My ePortfolio Register   

New trastuzumab combinations for HER2 positive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.11.11
Views: 3163

Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium

There has been great progress made in treatment of HER2 positive breast cancer largely due to the results of trastuzumab, however a number of new drugs have been developed that can treat this disease after trastuzumab has failed. The monoclonal antibody pertuzumab and the tyrosine kinase inhibitor lapatinib have very different modes of action but both form effective drug combinations with trastuzumab. This dual HER2 blockade approach has shown promising results both in early trials in the advanced setting and in early neoadjuvant trials. Dr Martine Piccart discusses the design and outcome of these studies and explains how effectively determining which patients will response most to these treatments could help reduce cancer treatment cost and level of adverse effects.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence